long intergenic non-protein coding RNA 1359Genealiases: []
Q-omics provides the consensus-scored LINC01359 profile across patient tissues and cancer cell-line models. LINC01359 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC01359 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LINC01359 RNA expression shows 19,489 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where LINC01359 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01359 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01359 survival associations across molecular data types. LINC01359 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01359 RNA expression–survival associations across cancer types. High LINC01359 expression shows unfavorable associations in UVM, but favorable associations in MESO, BLCA, BRCA, LAML and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC01359 RNA expression.
This table summarizes LINC01359 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01359. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01359 shows lower tumor expression in LUSC, UCEC, BRCA and KIRP and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher LINC01359 RNA expression in tumor versus normal tissue (log2 FC = +0.185, t-test p < 0.001).
This table shows molecular features associated with LINC01359 in patient tissues and cancer cell lines. In patient samples, LINC01359 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
